5 Analysts Have This to Say About Krystal Biotech
Portfolio Pulse from Benzinga Insights
Over the past three months, five analysts have published their opinion on Krystal Biotech (NASDAQ:KRYS) stock, all of them being bullish. The average price target given by these analysts is $144.8, which is higher than the current price of $124.0. However, this average has decreased by 2.16% from the previous average price target of $148.00.
September 07, 2023 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Analysts are bullish on Krystal Biotech with an average price target of $144.8, implying potential upside from the current price. However, the average target has decreased by 2.16% from the previous one.
The unanimous bullish sentiment from analysts indicates a positive outlook for Krystal Biotech. The average price target suggests potential upside, which could drive the stock price up in the short term. However, the decrease in the average target might indicate slightly reduced optimism.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100